Nikolaos Vassos1, Abbas Agaimy2, Werner Hohenberger3, Roland S Croner3. 1. Department of Surgery, University Hospital, Erlangen, Germany. Electronic address: nikolaos.vassos@uk-erlangen.de. 2. Department of Pathology, University Hospital, Erlangen, Germany. 3. Department of Surgery, University Hospital, Erlangen, Germany.
Abstract
BACKGROUND: Over the past decade, several changes occurred in diagnostics, treatment and understanding of pathogenesis of gastrointestinal stromal tumours (GIST). However, their coexistence with other malignancies of different histogenetic origin remains a challenging issue. METHODS: Patients diagnosed with GIST in a 10-years period were identified retrospectively and clinical history and findings thoroughly explored for the presence of associated other malignancies. Follow up data were obtained and analysed for prognostic impact of the concurrent malignancy and/or GIST. RESULTS: Thirty seven (27 males, 10 females) of 86 GIST-patients (43%) had another malignancy. Mean age was 70 years. Associated malignancies were gastrointestinal (n = 29; 69%), renal-/urological (n = 5; 12%), haematological (n = 4; 9.5%), cutaneous (n = 3; 7%) and thyroid (n = 1; 2.5%) in origin. Majority of GISTs occurred in stomach (65%) and small intestine (30.6%) and most (78%) were asymptomatic incidental findings during diagnostic or therapeutic procedures for associated malignancies. GIST size ranged from 0.1 cm to 9 cm (mean, 2.2 cm) and all of them had a low (<5/50 HPFs) or no mitotic activity. Thirty-one tumours (84%) were of no/very low/low risk and 6 were of intermediate risk. During follow-up (range 3-160 months, mean; 60 months), one patient suffered from distant metastases of GIST. Seven patients (19%) died of associated malignancies and three patients (8%) of other non-tumour-associated cause, but none died of GIST. CONCLUSION: Coexistence of GIST with other malignancies is higher than previously reported and should draw attention of clinicians towards these incidental findings. Prognosis in these patients is usually determined by other malignancy and not significantly influenced by GIST. Therefore treatment algorithms should be focused on prognostically relevant malignancy.
BACKGROUND: Over the past decade, several changes occurred in diagnostics, treatment and understanding of pathogenesis of gastrointestinal stromal tumours (GIST). However, their coexistence with other malignancies of different histogenetic origin remains a challenging issue. METHODS:Patients diagnosed with GIST in a 10-years period were identified retrospectively and clinical history and findings thoroughly explored for the presence of associated other malignancies. Follow up data were obtained and analysed for prognostic impact of the concurrent malignancy and/or GIST. RESULTS: Thirty seven (27 males, 10 females) of 86 GIST-patients (43%) had another malignancy. Mean age was 70 years. Associated malignancies were gastrointestinal (n = 29; 69%), renal-/urological (n = 5; 12%), haematological (n = 4; 9.5%), cutaneous (n = 3; 7%) and thyroid (n = 1; 2.5%) in origin. Majority of GISTs occurred in stomach (65%) and small intestine (30.6%) and most (78%) were asymptomatic incidental findings during diagnostic or therapeutic procedures for associated malignancies. GIST size ranged from 0.1 cm to 9 cm (mean, 2.2 cm) and all of them had a low (<5/50 HPFs) or no mitotic activity. Thirty-one tumours (84%) were of no/very low/low risk and 6 were of intermediate risk. During follow-up (range 3-160 months, mean; 60 months), one patient suffered from distant metastases of GIST. Seven patients (19%) died of associated malignancies and three patients (8%) of other non-tumour-associated cause, but none died of GIST. CONCLUSION: Coexistence of GIST with other malignancies is higher than previously reported and should draw attention of clinicians towards these incidental findings. Prognosis in these patients is usually determined by other malignancy and not significantly influenced by GIST. Therefore treatment algorithms should be focused on prognostically relevant malignancy.
Authors: Shawn J Mendonca; Alejandro Sanchez; Kyle A Blum; Mazyar Ghanaat; Mahyar Y Kashan; Nicole Benfante; Paul Russo; Jonathan A Coleman; Aimee M Crago; A Ari Hakimi Journal: J Surg Oncol Date: 2018-06-07 Impact factor: 3.454
Authors: J A Fernández; V Olivares; A J Gómez-Ruiz; B Ferri; M D Frutos; T Soria; G Torres; P Parrilla Journal: Clin Transl Oncol Date: 2018-10-27 Impact factor: 3.405
Authors: K Kramer; S Wolf; B Mayer; S A Schmidt; A Agaimy; D Henne-Bruns; U Knippschild; M Schwab; M Schmieder Journal: Neoplasia Date: 2015-01 Impact factor: 5.715
Authors: Klaus Kramer; Uwe Knippschild; Benjamin Mayer; Kira Bögelspacher; Hanno Spatz; Doris Henne-Bruns; Abbas Agaimy; Matthias Schwab; Michael Schmieder Journal: BMC Cancer Date: 2015-02-14 Impact factor: 4.430